Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Use Reduces Risk of Early-Onset Colorectal Cancer in Patients with Type 2 Diabetes-Mellitus (T2DM)

被引：0
|
作者：
Olasehinde, Temitope [1 ]
Cooper, Gregory [1 ]
Perez, Jaime A. [1 ]
机构：
[1] Case Western Reserve Univ, Univ Hosp, Cleveland Med Ctr, Dept Neurol, Cleveland, OH USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001031256.48901.46
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S472
引用
收藏
页码：S329 / S330
页数：2
相关论文
共 50 条
  • [41] Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study
    Lassen, Mats C. H.
    Johansen, Niklas Dyrby
    Modin, Daniel
    Catarig, Andrei-Mircea
    Vistisen, Bodil Kjeldgaard
    Amadid, Hanan
    Zimmermann, Esther
    Gislason, Gunnar
    Biering-Sorensen, Tor
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5239 - 5250
  • [42] Efficacy and safety of IDegLira (combination of insulin degludec and liraglutide) in insulin-naive patients with Type 2 diabetes inadequately controlled on glucagon-like peptide-1 receptor agonist(GLP-1RA) therapy
    Viljoen, A.
    Linjawi, S.
    Bode, B. W.
    Chaykin, L. B.
    Courreges, J-P
    Handelsman, Y.
    Lehmann, L. M.
    Mishra, A.
    Simpson, R. W.
    DIABETIC MEDICINE, 2016, 33 : 63 - 64
  • [43] In insulin-naive patients with Type 2 diabetes inadequately controlled on a glucagon-like peptide-1 receptor agonist (GLP-1RA), IDegLira (combination of insulin degludec and liraglutide) resulted in improved patient-reported outcomes vs unchanged GLP-1RA
    Russell-Jones, D.
    Brod, M.
    Linjawi, S.
    Bode, B. W.
    Chaykin, L. B.
    Courreges, J. P.
    Handelsman, Y.
    Kongso, J. H.
    Reiter, P. D.
    Simpson, R. W.
    DIABETIC MEDICINE, 2016, 33 : 68 - 68
  • [44] Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?
    Juris J Meier
    Michael A Nauck
    Nature Clinical Practice Endocrinology & Metabolism, 2008, 4 : 606 - 607
  • [45] Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?
    Meier, Juris J.
    Nauck, Michael A.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (11): : 606 - 607
  • [46] Glucagon-Like Peptide-1 Receptor Agonists Reduction in Stroke Type 2 DM Patients
    Alhawyan, Fatmah Salem
    Althobaiti, Mohammed Adel
    Alnami, Hashim Yahya
    Allahafi, Hadeel Ibrahim
    Almalky, Ayman Jamaan
    Al Johani, Sultan Ahmed
    Shiban, Rokayah Hussain
    Saddah, Mohammed Ahmed
    Alamrah, Hussam Mohammed
    Aljuhani, Moayad Zeyad
    Alfallaj, Ebtehal Hamid
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND PHYTOPHARMACOLOGICAL RESEARCH, 2020, 10 (05): : 122 - 128
  • [47] Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
    Babenko, Alina Yu.
    Savitskaya, Daria A.
    Kononova, Yulia A.
    Trofimova, Aleksandra Yu.
    Simanenkova, Anna V.
    Vasilyeva, Elena Yu.
    Shlyakhto, Evgeny V.
    JOURNAL OF DIABETES RESEARCH, 2019, 2019
  • [48] A Phase 1b/2a Study of the Safety and Tolerability of GSBR-1290, a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA), in Healthy Overweight/Obese Volunteers (HOV) and Participants with Type 2 Diabetes Mellitus (T2DM)
    Coll, Blai
    Zhang, Jinqiang
    Chen, Libo
    Ibarra, Lani
    Yue, Huibin
    Barth, Aline
    Bach, Mark A.
    DIABETES, 2024, 73
  • [49] TTP054, a Novel, Orally-Available Glucagon-Like Peptide-1 (GLP-1) Agonist: Results from a 28 Day Study in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Gustavson, Stephanie M.
    Wang, Shulin
    Valcarce, Carmen
    Clark, David
    Grimes, Imogene M.
    Orlandi, Cesare
    DIABETES, 2013, 62 : A29 - A30
  • [50] Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell, Sheila A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (03) : 371 - 377
12345